Skip to main content
. Author manuscript; available in PMC: 2022 Jan 27.
Published in final edited form as: ACS Appl Bio Mater. 2021 Aug 25;4(9):6658–6663. doi: 10.1021/acsabm.1c00717

Figure 2.

Figure 2.

(A) Percentage binding of Gd-S6, Closo-MRA and MS-325 with HSA (4.5% w/v = 0.67 mM) in PBS at pH 7.4 and 37 °C. (B) In vivo dynamic contrast enhanced MRA of Closo-MRA in CF1 mice at various time points post injection at 0.1 mmol/kg Gd3+ dose and 7 T. (C) Blood vessel contrast enhancement ratio (CER) of Closo-MRA (solid dot) significantly higher than that of Gd-DTPA-BMA (open circle) at all time points up to 3 h (p < 0.01).